This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
OSMT or QGEN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
OSMT vs. QGEN: Which Stock Is the Better Value Option?
QIAGEN Rides on Solid QuantiFERON-TB Sales Amid Several Woes
by Zacks Equity Research
QIAGEN (QGEN) pins hopes on its key strategic collaborations with Hamilton Robotics and Tecan for the pre-analytical handling of blood tubes.
QIAGEN (QGEN) Catches Eye: Stock Jumps 9.9%
by Zacks Equity Research
QIAGEN (QGEN) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.
QIAGEN (QGEN) Beats Q3 Earnings Estimates, Cuts Revenue View
by Zacks Equity Research
We are impressed with QIAGEN's (QGEN) year-over-year growth across majority of operating segments in Q3.
Qiagen (QGEN) Tops Q3 Earnings Estimates
by Zacks Equity Research
Qiagen (QGEN) delivered earnings and revenue surprises of 2.86% and -0.26%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Qiagen (QGEN) Q3 Earnings Preview: What's in the Cards?
by Zacks Equity Research
Qiagen (QGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
QIAGEN (QGEN) Launches QIAseq FastSelect Technology Kits
by Zacks Equity Research
The launch of the kits is expected to bolster QIAGEN's (QGEN) Life Sciences Business Area
QIAGEN Down on Dim Q3 Prelim Sales, Startling CEO Departure
by Zacks Equity Research
If the dismal preliminary sales performance was not enough, then the news pertaining to QIAGEN's (QGEN) current CEO Peer M. Schatz's stepping down came as another huge blow.
QIAGEN Inks Deal With Illumina to Deliver NGS-Based IVD Kits
by Zacks Equity Research
QIAGEN (QGEN) aims to fast-track the adoption of NGS-based IVD test and improve patient outcomes through the new partnership deal.
Illumina (ILMN) Inks Deal to Commercialize NGS-Based IVD Kits
by Zacks Equity Research
Illumina (ILMN) aims to expand access to NGS-based IVD test kits and improve patient outcomes through the new partnership deal.
QIAGEN (QGEN) Hurt by Low QuantiFERON-TB Sales & FX Headwind
by Zacks Equity Research
Poor QuantiFERON-TB sales in Americas and an unfavourable currency translation affect QIAGEN's (QGEN) overall performance.
Qiagen (QGEN) Down 8.7% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
QIAGEN Posts QIAstat-Dx Gastrointestinal Panel Study Results
by Zacks Equity Research
The study outcome has been a major step for QIAGEN (QGEN) toward offering accurate diagnosis and treatment of gastroenteritis.
Inovio (INO) Q2 Earnings & Revenues Fall Shy of Estimates
by Zacks Equity Research
Inovio Pharmaceuticals (INO) disappoints with earnings and revenue miss in the second quarter. Shares depreciate in after-hours trading.
QIAGEN (QGEN) Misses Q2 Earnings Estimates, Lowers View
by Zacks Equity Research
QIAGEN (QGEN) registers revenue growth across majority of its geographies in Q2.
Qiagen (QGEN) Q2 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Qiagen (QGEN) delivered earnings and revenue surprises of -2.94% and -1.24%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Qiagen (QGEN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Qiagen (QGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Inovio Ends Enrollment in Vulvar Dysplasia Study on VGX-3100
by Zacks Equity Research
Inovio (INO) closes enrollment in the phase II study, evaluating VGX-3100 for the treatment of HPV-related vulvar dysplasia.
Inovio Up on Enrollment Closure in Cervical Dysplasia Study
by Zacks Equity Research
Inovio (INO) concludes enrollment in the phase III study (REVEAL 1), which currently evaluates VGX-3100 for the treatment of cervical dysplasia, caused by HPV. Shares rally.
QIAGEN Inks Distribution Deal With Mckesson Medical-Surgical
by Zacks Equity Research
The distribution agreement will enable QIAGEN (QGEN) to expand reach in the healthcare market.
Here's Why You Should Hold on to QIAGEN (QGEN) Stock Now
by Zacks Equity Research
QIAGEN (QGEN) is enjoying investors' high confidence, courtesy of the QIAstat-Dx system.
QIAGEN-DiaSorin Union to Enhance QuantFERON for Lyme Disease
by Zacks Equity Research
QIAGEN (QGEN) expects multi-site clinical validations for this new system during 2020 Lyme disease season.
Qiagen (QGEN) Up 4% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
QIAGEN (QGEN) Launches PIK3CA Kit for Breast Cancer Patients
by Zacks Equity Research
QIAGEN's (QGEN) therascreen PIK3CA Kit is the first companion diagnostic test to have attained premarket approval from the FDA.